Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 2/20 | 0.35 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 12/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13613878 | 0.90 | ALOX5 (0.36) | CYP26A1CYP26B1MCHR1ALOX5PTGS1 | |
| SCHEMBL13613851 | 0.88 | CYP26A1 (0.35) | CYP26A1CYP26B1ALOX5PTGS1PTGS2 | |
| SCHEMBL13986034 | 0.84 | CYP26B1 (0.51) | CYP26A1CYP26B1ALOX5PTGS1PTGS2 | |
| SCHEMBL14524821 | 0.83 | PTGS2 (0.36) | CYP26A1CYP26B1ALOX5PTGS1PTGS2 | |
| SCHEMBL13986015 | 0.81 | CYP26A1 (0.40) | CYP26A1CYP26B1ALOX5PTGS1PTGS2 | |
| SCHEMBL4523320 | 0.77 | CYP26A1 (0.34) | CYP26A1CYP26B1ALOX5PTGS1PTGS2 | |
| SCHEMBL4517390 | 0.72 | ABCB11 (0.42) | CYP26A1CYP26B1ALOX5PTGS1PTGS2 | |
| SCHEMBL4512937 | 0.71 | CYP26A1 (0.31) | CYP26A1CYP26B1ALOX5PTGS1PTGS2 | |
| SCHEMBL4521493 | 0.71 | CYP26A1 (0.49) | CYP26A1CYP26B1AKR1B1 | |
| SCHEMBL4511996 | 0.70 | CYP26A1 (0.39) | CYP26A1CYP26B1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638648-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7468391-B2 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | CYP26A1 15/4885CYP26B1 10/4885MCHR1 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.